SEC Company Response from ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514) (ADMA) — Nov 6, 2017
ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)
Date: Nov. 6, 2017 · CIK: 0001368514 · Accession: 0001193805-17-003396
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-220910
Letter
RAYMOND JAMES & ASSOCIATES, INC.
880 Carillon Parkway
St. Petersburg, Florida 33716
November 6, 2017
VIA EDGAR
U.S. Securities and Exchange Commission
100 F St., NE
Washington D.C. 20549
Attention:
Irene J. Paik, Attorney Adviser
Re:
ADMA Biologics, Inc.
Registration Statement on Form S-1 (File No. 333-220910)
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Raymond James & Associates Inc., as representative of the underwriters, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:30 p.m. Eastern Time on November 8, 2017, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with, or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
Very truly yours,
RAYMOND JAMES & ASSOCIATES, INC.
Show Raw Text
CORRESP
1
filename1.htm
RAYMOND JAMES & ASSOCIATES, INC.
880 Carillon Parkway
St. Petersburg, Florida 33716
November 6, 2017
VIA EDGAR
U.S. Securities and Exchange Commission
100 F St., NE
Washington D.C. 20549
Attention:
Irene J. Paik, Attorney Adviser
Re:
ADMA Biologics, Inc.
Registration Statement on Form S-1 (File No. 333-220910)
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules
and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Raymond James &
Associates Inc., as representative of the underwriters, hereby requests acceleration of the effective date of the above-referenced
Registration Statement so that it will become effective at 4:30 p.m. Eastern Time on November 8, 2017, or as soon thereafter
as practicable.
Pursuant to Rule 460 under the Securities
Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited to participate
in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable
to secure adequate distribution of the preliminary prospectus.
The undersigned confirms that it has complied
with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied
with, or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the
above-referenced issue.
Very truly yours,
RAYMOND JAMES & ASSOCIATES, INC.
By:
/s/ Ed Newman